Semaglutide Weight Management and Cardiovascular Risk Reduction

The safety profile of oral semaglutide 25 and 50 mg was generally consistent with the GLP-1 receptor agonist drug class Oral semaglutide Oral semaglutide 14 mg (n = 534) 25 mg (n = 534) Oral semaglutide 50 mg (n = 534) n % n % n % AEs 404 (75.7) 422 (79.0) 428 (80.1) Gastrointestinal adverse events 225 (42.1) 282 (52.8) 286 (53.6) Serious AEs 53 (9.9) 57 (10.7) 44 (8.2) AEs leading to drug withdrawal 54 (10.1) 66 (12.4) 68 (12.7) GLP-1: Glucagon like peptide-1; AE: Adverse event; T2D: Type 2 diabetes Safety: • Majority of gastrointestinal adverse events were mild or moderate in severity The majority occurred during dose escalation In the trial, oral semaglutide 25 and 50 mg appeared to have a safe and well-tolerated profile

View entire presentation